Can the new CEO at Genentech maintain a tradition of groundbreaking R&D?
During the 6 years that Ian Clark managed Genentech as its CEO, he never lost sight of the singular mission he had at the big Roche subsidiary. Like Pascal Soriot before him, and now Bill Anderson coming in after his departure at the end of this year, job 1 at Genentech is keeping the pharma giant’s uniquely productive R&D operation focused on big new products.
That job profile hasn’t changed one bit. This is what Roche’s Daniel O’Day, CEO of Roche’s pharma division, had to say on Clark’s replacement at the helm:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.